TY - JOUR
T1 - Psoriatic Arthritis
T2 - The Influence of Co-morbidities on Drug Choice
AU - Patel, Sneha
AU - Kumthekar, Anand
N1 - Funding Information:
No funding or sponsorship was received for this study or publication of this article. The Rapid Service Fee was funded by the authors.
Publisher Copyright:
© 2021, The Author(s).
PY - 2022/2
Y1 - 2022/2
N2 - Psoriatic arthritis (PsA) is associated with a higher burden of co-morbidities such as obesity, cardiovascular disease, non-alcoholic fatty liver disease, inflammatory eye disease, inflammatory bowel disease, skin cancer and depression compared to the general population. In the last 20 years, the therapeutic options for PsA have increased exponentially with the availability of tumor necrosis factor-alpha (TNF) inhibitors, interleukin (IL)-17 inhibitors, IL-12/23 inhibitors and Janus kinases/signal transducer and activator of transcription proteins (JAK/STAT) inhibitors. The articular and extra-articular manifestations of PsA usually dictate the treatment choice but important consideration must be given to the corresponding co-morbidities while deciding the drug therapy due to associated safety profile, effect on disease activity, etc. This review provides a comprehensive review of common co-morbidities in PsA and how they can influence treatment choices.
AB - Psoriatic arthritis (PsA) is associated with a higher burden of co-morbidities such as obesity, cardiovascular disease, non-alcoholic fatty liver disease, inflammatory eye disease, inflammatory bowel disease, skin cancer and depression compared to the general population. In the last 20 years, the therapeutic options for PsA have increased exponentially with the availability of tumor necrosis factor-alpha (TNF) inhibitors, interleukin (IL)-17 inhibitors, IL-12/23 inhibitors and Janus kinases/signal transducer and activator of transcription proteins (JAK/STAT) inhibitors. The articular and extra-articular manifestations of PsA usually dictate the treatment choice but important consideration must be given to the corresponding co-morbidities while deciding the drug therapy due to associated safety profile, effect on disease activity, etc. This review provides a comprehensive review of common co-morbidities in PsA and how they can influence treatment choices.
KW - Co-morbidities
KW - Drug therapy
KW - Psoriatic arthritis
UR - http://www.scopus.com/inward/record.url?scp=85119529342&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85119529342&partnerID=8YFLogxK
U2 - 10.1007/s40744-021-00397-7
DO - 10.1007/s40744-021-00397-7
M3 - Review article
AN - SCOPUS:85119529342
SN - 2198-6576
VL - 9
SP - 49
EP - 71
JO - Rheumatology and Therapy
JF - Rheumatology and Therapy
IS - 1
ER -
